[1] Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study[J]. Lancet Gastroenterol Hepatol, 2023,8(10):879-907.
[2] Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma[J]. Gut, 2022,71(3):616-626.
[3] Sung W K, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma[J]. Nat Genet, 2012,44(7):765-769.
[4] Tu T, Budzinska M A, Shackel N A, et al. HBV DNA integration: molecular mechanisms and clinical implications[J]. Viruses, 2017,9(4):75.
[5] Chen L, Zhang C, Xue R, et al. Deep whole-genome analysis of 494 hepatocellular carcinomas[J]. Nature, 2024,627(8004):586-593.
[6] Kiyose H, Nakagawa H, Ono A, et al. Comprehensive analysis of full-length transcripts reveals novel splicing abnormalities and oncogenic transcripts in liver cancer[J]. PLoS Genet, 2022,18(8):e1010342.
[7] Sivasudhan E, Blake N, Lu Z, et al. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review[J]. Cells, 2022,11(4):741.
[8] Lefeuvre C, Le Guillou-Guillemette H, Ducancelle A. A pleiotropic role of the hepatitis b virus core protein in hepatocarcinogenesis[J]. Int J Mol Sci, 2021,22(24):13651.
[9] Liu W, Cai S, Pu R, et al. HBV preS mutations promote hepatocarcinogenesis by inducing endoplasmic reticulum stress and upregulating inflammatory signaling[J]. Cancers (Basel), 2022,14(13):3274.
[10] Liang Y J, Teng W, Chen C L, et al. Clinical implications of HBV PreS/S mutations and the effects of PreS2 deletion on mitochondria, liver fibrosis, and cancer development[J]. Hepatology, 2021,74(2):641-655.
[11] Shoraka S, Hosseinian S M, Hasibi A, et al. The role of hepatitis B virus genome variations in HBV-related HCC: effects on host signaling pathways[J]. Front Microbiol, 2023,14:1213145.
[12] Lefeuvre C, Roux M, Blanchard S, et al. Analysis of hepatic fibrosis markers in the serum of chronic hepatitis B patients according to basal core promoter/precore mutants[J]. Sci Rep, 2022,12(1):10261.
[13] Yang D, Zou J, Guan G, et al. The A1762T/G1764A mutations enhance HBV replication by alternating viral transcriptome[J]. J Med Virol, 2023,95(10):e29129.
[14] D'Souza S, Lau K C, Coffin C S, et al. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma[J]. World J Gastroenterol, 2020,26(38):5759-5783.
[15] Elizalde M M, Tadey L, Mammana L, et al. Biological characterization of hepatitis B virus genotypes: their role in viral replication and antigen expression[J]. Front Microbiol, 2021,12:758613.
[16] Tsushima K, Tsuge M, Hiraga N, et al. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice[J]. J Gastroenterol, 2019,54(7):650-659.
[17] Lin Y, Gao Z X, Shen X, et al. Correlation between polymorphisms in toll-like receptor genes and the activity of hepatitis B virus among treatment-nave patients: a case-control study in a Han Chinese population[J]. BMC Infect Dis, 2018,18(1):28.
[18] Chen Y, Yang X, Chen Y, et al. Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma[J]. BMC Cancer, 2021,21(1):615.
[19] Liu Y, Wu Q, Zhang F, et al. Antioxidants-related nuclear factor erythroid 2-related factor 2 gene variants associated with HBV-related liver disease[J]. Cancer Cell Int, 2023,23(1):72.
[20] 李莹,廖宇圣,孙圣斌,等. 血清IL-17与IL-17-197A/G位点单核苷酸多态性和乙型病毒性肝炎易感性研究[J].中华医院感染学杂志, 2020, 30(11): 1647-1650.
[21] Zeng Z, Liu H, Xu H, et al. Genome-wide association study identifies new loci associated with risk of HBV infection and disease progression[J]. BMC Med Genomics, 2021,14(1):84.
[22] Sekiba K, Otsuka M, Funato K, et al. HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA[J]. J Hepatol, 2022,76(1):53-62.
[23] Kusunoki H, Sakamoto T, Kobayashi N, et al. Structural insights into the interaction between the C-terminal-deleted BH3-like motif peptide of hepatitis B virus X protein and Bcl-x(L)[J]. Biochemistry, 2024,63(5):632-643.
[24] Naully P G, Tan M I, Agustiningsih A, et al. cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B[J]. Ann Hepatol, 2024,30(1):101533.
[25] Liu W, Yao Q, Su X, et al. Molecular insights into Spindlin1-HBx interplay and its impact on HBV transcription from cccDNA minichromosome[J]. Nat Commun, 2023,14(1):4663.
[26] Lei Y, Xu X, Liu H, et al. HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G(1)/S cycle[J]. Autophagy, 2021,17(12):4423-4441.
[27] Li Y, Wang F, Geng Z, et al. HBx promotes tumorigenicity through RRM2-mediated autophagy in hepatocellular carcinoma[J]. Cell Biosci, 2024,14(1):116.
[28] Ling L R, Zheng D H, Zhang Z Y, et al. Effect of HBx on inflammation and mitochondrial oxidative stress in mouse hepatocytes[J]. Oncol Lett, 2020,19(4):2861-2869.
[29] Yen C J, Lin Y J, Yen C S, et al. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma[J]. PLoS One, 2012,7(7):e41931.
[30] Yan W, Rao D, Fan F, et al. Hepatitis B virus X protein and TGF-β: partners in the carcinogenic journey of hepatocellular carcinoma[J]. Front Oncol, 2024,14:1407434.
[31] Bertoletti A, Kennedy P T F, and Durantel D. HBV infection and HCC: the 'dangerous liaisons'[J]. Gut, 2018,67(5):787-788.
[32] Khan M, Arooj S, and Wang H. NK cell-based immune checkpoint inhibition[J]. Front Immunol, 2020,11:167.
[33] Yu L, Sun L, Liu X, et al. The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus-related hepatocellular carcinoma[J]. Hepatol Res, 2023,53(5):417-431.
[34] Yu L, Liu X, Wang X, et al. TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Oncoimmunology, 2021,10(1):1942673.
[35] Gehring A J and Protzer U. Targeting innate and adaptive immune responses to cure chronic HBV infection[J]. Gastroenterology, 2019,156(2):325-337.
[36] Song A, Wang X, Lu J, et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis[J]. J Viral Hepat, 2021,28(4):601-612.
[37] Yip T C, Wong V W, Tse Y K, et al. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss[J]. Aliment Pharmacol Ther, 2021,53(2):321-331.
[38] Li H, Lu D, Chen J, et al. Post-transplant hepatitis B virus reactivation impacts the prognosis of patients with hepatitis B-related hepatocellular carcinoma: a dual-centre retrospective cohort study in China[J]. Int J Surg, 2024,110(4):2263-2274.
[39] Ding W B, Wang M C, Yu J, et al. HBV/Pregenomic RNA increases the stemness and promotes the development of HBV-related HCC through reciprocal regulation with insulin-like growth factor 2 mRNA-binding protein 3[J]. Hepatology, 2021,74(3):1480-1495.
[40] Hsieh Y C, Pan M H, Jeng W J, et al. Serum HBcrAg and hepatocellular carcinoma in a taiwanese population seronegative for HBsAg and anti-HCV[J]. Clin Gastroenterol Hepatol, 2023,21(5):1303-1313.e11.
[41] Chang K C, Lin M T, Wang J H, et al. HBcrAg predicts hepatocellular carcinoma development in chronic B hepatitis related liver cirrhosis patients undergoing long-term effective anti-viral[J]. Viruses, 2022,14(12):2671.
[42] Jeng W J, Papatheodoridis G V, Lok A S F. Hepatitis B[J]. Lancet, 2023,401(10381):1039-1052.
[43] Chiang C J, Yang Y W, You S L, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan[J]. JAMA, 2013,310(9):974-976.
[44] Wong G L, Hui V W, Yip T C, et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2022,56(5):869-877.
[45] Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial[J]. PLoS Med, 2014,11(12):e1001774. |
